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OBJECTIVES: Recent questions have been raised about ipratropium safety in chronic 
obstructive pulmonary disease (COPD). However, these studies have failed to examine 
potential beneﬁ ts of ipratropium. Our objective was to evaluate the comparative 
effectiveness of ipratropium versus other COPD medications. METHODS: We con-
ducted a cohort study in veterans diagnosed with COPD between October 2002
and September 2003. Patients were followed up to 2.5 years for all-cause mortality,
COPD exacerbations and COPD-related hospitalizations. Time-varying medication 
exposure was determined for inhaled corticosteroids (ICS), ipratropium (IPRA), long-
acting beta-agonists (LABA), and theophylline (THEO) during follow-up. Risk 
indices were used to divide the cohort into low, moderate and high risk groups. Cox 
proportional hazards regressions were used to examine associations between medica-
tion regimen exposure and events, stratiﬁ ed by risk index and adjusted for propensity 
to use ipratropium. RESULTS: From 108,426 patients, there were 16,539 deaths, 
42,109 with an exacerbation and 14,828 with a COPD-related hospitalization.
Compared with LABA, there was a signiﬁ cant increase in the mortality risk associated
with IPRA in the moderate (HR  1.54 [95% CI 1.19–2.01] and high risk (HR  1.30
([1.09–1.55]) groups. For exacerbations, IPRA was associated with an increased
risk in the low risk group (HR  1.64 [1.40–1.92]), but not in either the moderate
(HR  0.97 [0.85–1.09]) or high risk group (HR  0.94 [0.84–1.05]). CONCLU-
SIONS: We found an increased risk of mortality associated with ipratropium that
varied by baseline risk of event. The ﬁ ndings elevate concerns about potential harms 
associated with ipratropium in COPD that do not appear to be offset by reduction in 
COPD events.
PRS4
DRUG UTILIZATION AND SPENDING TRENDS FOR ANTI-ASTHMATIC
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OBJECTIVES: Asthma is a common chronic respiratory disease with an increasing
prevalence in industrialized countries. The purpose of this study was to describe
the drug utilization and spending trends for anti-asthmatic agents in the U.S. Medicaid
program. METHODS: A retrospective and descriptive study was conducted quarterly
prescriptions and reimbursement amount for each study drug in Medicaid Pharmacy 
claims ﬁ les which extracted from the Centers for Medicare & Medicaid Services 
from 1991 quarter 1 to 2007 quarter 3. The reimbursement per-prescription was 
calculated each quarter as a proxy of drug price. The study drugs included Short-
acting beta agonist (SABA), Long-acting beta agonist (LABA), Inhaled Corticosteroid 
(ICS) and Combination medication with LABA and ICS. RESULTS: The total number 
of prescriptions per quarter for asthma medications increased from 303,224 in 1991
to 1,091,201 in 2005, and dropped to 302,157 in 2007. From 1991 to 2005, the 
total number of prescriptions per quarter for SABA decreased from 278,286 to 37,965,
LABA increased from lower than 1,000 to 43,106, ICS increased from 24,938 to 
85,846 and LABA plus ICS increased from 61,477 to 924,284. The total reimburse-
ment per quarter of asthma medications increased from $23 million in 1991 to
$280 million in 2005 and dropped to $193 million in 2007. The per prescription 
price leaders among study drugs in 2007 are: Xopenex in SABA ($150 per pre-
scription), Serevent in LABA ($125 per prescription), Asmanex in ICS ($370 
per prescription) and Advair in LABA plus ICS ($184 per prescription). CONCLU-
SIONS: Total utilization and spending of asthma medications increased rapidly 
before 2005 which might primarily be due to 2002 asthma treatment guideline regard-
ing to drug use recommendations. New innovative combination drugs with LABA 
plus ICS had relatively higher per-prescription price. A signiﬁ cant decreasing of 
utilization and spending after 2005 might be due to the implementation of Medicare
Part D.
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OBJECTIVES: To assess the relationship between COPD exacerbations and controller 
therapy duration. METHODS: Data from 2 large US proprietary health claims data-
bases were pooled to construct a prevalent cohort of patients with COPD and an index
date deﬁ ned as ﬁ rst controller therapy ﬁ ll from January 1, 2004–March 31/2008.
Inclusion criteria were COPD diagnosis (ICD-9CM 491, 492, or 496), 12 months
of pre- and post-index date enrollment, 1 pharmacy claim, age 40 years, and 
no lung cancer. Controller therapy included inhaled corticosteroids, long-acting B-
agonists, ﬂ uticasone/salmeterol combination, or tiotropium bromide. Logistic regres-
sion models assessed the risk of exacerbation-related events (hospitalization, emergency
department (ED) visits, oral corticosteroid (OCS) or antibiotic prescriptions) associ-
ated with claim-identiﬁ ed therapy duration, controlling for age, sex, prior health 
care utilization, and comorbidities. RESULTS: Of the 45,657 patients (45%, men;
mean age, 60 years), 11.28% had a hospitalization; 2.70% an ED visit; 42.12%, an 
OCS prescription; and 74.99% an antibiotic prescription. The annual rate of events/
patient included 0.48 hospitalizations, 0.04 ED visits, 2.43 antibiotic prescriptions, 
and 1.18 OCS prescriptions. Controller therapy duration of claims for the cohort 
included 0–90 days in 51%, 91–180 days in 17%, 181–270 days in 11.5%, and
271–365 days in 20.4%. Compared with patients whose therapy lasted 1–90 days, 
the exacerbation event risk was no different from that for those with 91–180 days 
(odds ratio [OR], 0.98; 95%CI, 0.92,1.05), 9% higher for those with 181–270 
days (OR, 1.09; 95%CI, 1.01,1.18), and 10% higher for those with 271–365 days
(OR, 1.10; 95%CI 1.03,1.17). Similar trends were observed for each exacerbation 
event. CONCLUSIONS: The inverse relationship between controller therapy duration 
and COPD exacerbations, while potentially confounded by disease severity, suggests 
reducing symptoms earlier may improve controller therapy duration and reduce
exacerbation risk.
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OBJECTIVES: The purpose of this study was to integrate survival function with utility 
of quality of life to estimate the quality-adjusted life expectancy (QALE) and expected
loss of QALE for patients under prolonged mechanical ventilation (PMV). METHODS:
A total of 633 patients fulﬁ lled the deﬁ nition of PMV or under such a care for more
than 21 days, of which medical records were abstracted and linked to the National
Death Registry database of Taiwan to obtain the survival function. Among them we 
collected 71 subjects and assessed their quality of life by Taiwan version of EQ-5D. 
The survival function for an age and gender matched reference population was gener-
ated using the Monte Carlo method from the life table of the general population of 
Taiwan. Lifetime survival of the PMV patients were obtained using linear extrapola-
tion of a logit-transformed curve of the survival ratio between the PMV and reference 
populations. The survival probability for each time point was adjusted with the mean 
utility to obtain the QALE. RESULTS: One year survival rate were 33%. The life 
expectancy and loss of life expectancy were 32.99 months and 101.89 months in
patients with PMV, respectively. The QALE and loss of QALE in patients with slightly
clear consciousness were 12.37 quality-adjusted life months (QALM) and 85.39 
QALM, respectively. The sensitivity analysis of applying measurements from two 
proxies, namely, family care-givers and nurses, did not show a statistically signiﬁ cance
and the QALE in total patients with PMV were 9.47 and 8.54 QALM, respectively. 
CONCLUSIONS: Overall QALE of patients with PMV was poor and the loss of utility 
is big. We shall encourage per-protocol weaning procedure in the intensive care unit
and early signature for no resuscitation (DNR) when the patient’s consciousness was 
clear.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: Statins exert anti-inﬂ ammatory effects that may have a positive 
impact on asthma. This study explored the association of statin exposure with 
asthma-related events and costs. METHODS: This was a retrospective analysis of the 
12 million person Medco National Integrated Database. Adult patients receiving
inhaled corticosteroid (ICS) therapy between January 2006 to December 2006, and
q1 hospitalization/emergency room (ER) visit for asthma (ICD9 493.XX) in the previ-
ous 12 months from ﬁ rst-occurring ICS prescription were selected. Patients were then 
stratiﬁ ed by statin exposure, and were followed for 1 year to assess the risk of the 
primary event endpoint of asthma-related hospitalization/ER visit (ICD9 493.XX). 
Event costs per patient-year of follow-up (2009 $US) were calculated using age-speciﬁ c 
Healthcare Cost and Utilization Project (HCUP) data for ICD9 493.XX-related 2006 
hospitalization and 2005 ER events inﬂ ated by 5%/year. Costs were derived from 
HCUP charges applying an actual cost : charge ratio of 0.4 for hospitalization, and an 
estimated ratio of 0.6 for ER visits. RESULTS: A total of 6574 patients were studied 
(4471 statin-unexposed; 2103 statin-exposed). Overall mean o SD age was 61 o 16 
years, 29% were male, and 19% had q2 asthma hospitalization/ER events in the previ-
ous 12 months. Asthma therapy included beta agonists (short-acting 63%; long-acting 
37%) and leukotriene modiﬁ ers (38%). Hospitalization/ER event incidence was
29.4% in statin-unexposed patients versus 20.5% in statin-exposed patients [odds
ratio 0.67 (95% CI 0.58–0.76; p  0.0001) adjusted for age, gender, previous asthma 
events and asthma therapy]. Hospitalization/ER event costs per pt-year were $1354
in statin-treated patients and $1123 in untreated patients ($230; 17%). Statin 
therapy reduced both hospitalization ($252 per pt-yr; 18%) and ER ($63 per pt-yr; 
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43%) end point costs. CONCLUSIONS: Statin exposure signiﬁ cantly reduced the
risk of recurrent asthma-related hospitalization/ER events and associated costs over
12 months in this analysis of ICS-treated adult asthmatic patients.
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OBJECTIVES: There is an attribution of smoking morbidity about 30% relate to lung
cancer (LC), about 20% relate to cardiovascular diseases (CVD) eg. myocardial infarc-
tion (MI) and stroke and about 75% of patients with chronic obstructive pulmonary 
disease (COPD). The main objective of this study was to determine direct medical 
costs related to smoking in Slovakia and the deﬁ ned costs of smoking cessation.
METHODS: Direct medical costs were evaluated from data collected in 2007 from 
the General Health Insurance Company, the largest one in Slovakia, covering 55% of 
all 5,400,000 inhabitants. The results were recalculated to the whole population. The 
costs were quoted in 2007 prices. RESULTS: The smoking costs of those patients 
treated on LC were €19,726,950; on COPD they were €19,454,040; on stroke they
were €6,019,778 and on MI they were €26,247,289. It was 33.66% from total direct
costs €212,243,357 assigned to these diseases and 2.15 % of total Slovakia health
care budget. The cost of treating a smoker on diseases associated with smoking was 
€1,114. Decreasing the number of smokers by 10% will reduce health care costs by
€7,144,806 per year, i.e. 0.22% from total budget. The cost of treatment to stop 
smoking using varenicline was €919 per patient. CONCLUSIONS: The direct costs
associated with smoking comprise an important part of total health care budget in
Slovakia. They signalize the need to establish effective strategies for smoking cessation. 
44% clinical effectiveness of varenicline shows to be a cost-effective way in reducting 
smoking and decreasing health care expenditures.
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OBJECTIVES: Omalizumab (Xolair) is an FDA-approved immunomodulator for the 
treatment of steroid refractory, uncontrolled (symptomatic), moderate-severe persis-
tent asthma in patients 12 years of age with a positive skin test to a perennial aeroal-
lergen. Our objective was to estimate the budget impact of omalizumab availability 
on a hypothetical health plan (US payer perspective). METHODS: The budget impact
was estimated as the difference in two scenarios where omalizumab is used by moder-
ate-severe uncontrolled asthmatics with a conﬁ rmed allergic component over similar 
controlled asthma patients on standard of care. Publicly available, real-world utiliza-
tion data were used to develop percentage estimates for omalizumab-eligible patients 
hierarchically as follows: treated asthmatics in the approved age-groups who exhibited
poor symptom control (55% of patients) and were moderate-severe asthmatics (40%) 
with IgE mediated asthma (60%) and whose IgE levels were within the approved
range per the omalizumab package insert (61%) were included in the model. Of these, 
based on real world utilization data, 3.2% would receive omalizumab therapy. Omali-
zumab-related costs in the model consisted of eligibility screening, drug, and ofﬁ ce
administration. Health service costs impacted by omalizumab consisted of unsched-
uled asthma-related exacerbation ofﬁ ce visits, emergency room visits, and hospitaliza-
tions. The impact of key model parameters on the budget was assessed in sensitivity 
analyses (SA). RESULTS: The incremental cost of omalizumab-treated patients 
was estimated at $1285 per omalizumab user per month or $0.11 per member per 
month (PMPM) given the additive costs of omalizumab screening, drug and adminis-
tration. When parameters were varied / 10% in a one-way sensitivity analysis, the
PMPM varied within $0.10 to $0.125. Results were most sensitive to the estimated
percentage of patients on omalizumab. CONCLUSIONS: The model demonstrated
that omalizumab availability resulted in an incremental cost of $0.11 PMPM. System-
atic variation of the model parameters by / 10% in the SA resulted in a PMPM 
range of $0.10–$0.125.
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OBJECTIVES: Cigarette smoking imposes a signiﬁ cant burden on employers as a 
consequence of increased absenteeism and smoking-related breaks during the working 
day. Despite the evidence supporting the efﬁ cacy and cost-effectiveness of smoking 
cessation treatments (SCTs), relatively few private drug plans reimburse such treat-
ments. The objectives of this study were to calculate the projected budget impact 
and return on investment for an employer funded drug plan in Canada in the ﬁ rst 3 
years of introducing SCT coverage. METHODS: A recently published state-transition 
model reﬂ ecting relevant smoking statuses was used for the analyses. The model 
involves a comparison of the clinical and economic outcomes for a hypothetical cohort
of 10,000 Canadian workers followed for three years. The relative efﬁ cacy of various
smoking cessation strategies (varenicline, bupropion, nicotine replacement therapy
and unaided cessation) were taken from the literature. Canadian data were used to
determine the population of smokers, marketplace dynamics, SCT costs, smoking-
related absenteeism and lost productivity. One-way sensitivity analyses were per-
formed. RESULTS: The analysis lead to an estimate of 1,801 employees who were
smokers at baseline. An estimated incremental total of 79 smokers would successfully 
quit smoking by the end of the 3-year time horizon with a SCT reimbursement 
program compared with a no coverage scenario. Budget impact associated with the
SCT coverage scenario equated to $164,182 while projected savings to employers were 
estimated at $381,292 over 3 years. This represented projected net savings to employ-
ers of $217,110 and a return on investment of $2.32 for every dollar spent to support 
a SCT reimbursement program. One-way sensitivity analyses conﬁ rmed the robustness 
of the ﬁ ndings. CONCLUSIONS: For a relatively modest investment, a SCT reim-
bursement program in the Canadian workplace is likely to reduce the number of 
smokers in the workforce, while generating a positive return on investment for 
employers within a short timescale.
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OBJECTIVES: To estimate the costs and beneﬁ ts of Timing Pharmaceutical
Intervention (TPI) through an example of asthma in Alberta, Canada. METHODS:
We included changes in direct health care and lost productivity costs, and Health
Related Quality of Life (HRQOL) among Alberta’s asthmatic adults (18 years
and over) in a one year time period. Health care costs and beneﬁ ts were estimated
through the effects of TPI on drug uses and health care utilization patterns, including 
hospital days, ER visits and physician visits. Productivity and HRQOL beneﬁ ts 
were estimated through the effects of TPI on the number of symptom free days 
(SFDs) of patients at age 18–64 and at all adult ages respectively. Health care
utilization rates, unit costs, SFDs days and HRQOL index scores from the literature
were used for analyses. The costs were adjusted to 2006 Canadian dollar value. 
RESULTS: In a year, in addition to a saving of $0.2–$0.3 million in health care 
costs, TPI on asthma generates a beneﬁ t of $12–$19 million in terms of improved
productivity and 22–29 quality adjusted life years in terms of improved HLQOL. 
CONCLUSIONS: The costing model provides us with a rough indication of the eco-
nomic impact of TPI. It is not expected that TPI will always yield net savings in terms 
of health care costs for all chronic conditions. This will depend on speciﬁ c diseases 
and the cost effectiveness of the intervention among the target population. However, 
other beneﬁ ts, such as improved HRQOL and productivity, should be considered in 
the decision making.
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OBJECTIVES: To compare the health care costs of children with newly-diagnosed
allergic rhinitis (AR) who subsequently received allergy immunotherapy (IT) to a
matched group of children with newly-diagnosed AR who did not receive IT. 
METHODS: We examined 10 years (1997–2007) of Florida Medicaid paid claims 
to identify children (18 years) newly diagnosed with AR who received IT and 
had at least 18 months of data following IT initiation (IT Group). Patients
were matched (by age at AR diagnosis, sex, race, and presence of asthma, atopic 
dermatitis, or conjunctivitis) over the same period to newly AR-diagnosed children 
who did not subsequently receive IT (Control Group). Wilcoxon signed-rank tests
compared 2-year, median, per-patient total health care costs (pharmacy costs 
inpatient costs  outpatient costs  IT costs if any) at 3, 6, 12, and 18 months.
RESULTS: Among 3,240,046 Florida Medicaid-enrolled children, 196,687 (6%) 
were newly diagnosed with AR, and 3,931 (2%) subsequently received IT. A subset 
(N  2,291) had at least 18 months of follow-up data and were matched to one or 
more of 71,790 controls. Within three months of IT initiation, the IT Group incurred
signiﬁ cantly lower total health care costs ($1,006 vs. $1,365, p  0.0001) than the 
matched Control Group. Signiﬁ cant cost savings were maintained across 6 months 
($1,810 vs. $2,474, p  0.0001), 12 months ($3,242 vs. $4,519, p  0.0001), and 
18 months ($4,329 vs. $6,138, p  0.0001), growing from $359 at 3 months to $1,809
at 18 months. In contrast, the 3-, 6-, 12-, and 18-month per-patient median cost
of IT was $250, $360, $488, and $565, respectively. CONCLUSIONS: This is the 
ﬁ rst U.S.-based study to report signiﬁ cant health care cost savings for IT among
AR-diagnosed children. Findings suggest that these savings may occur within a few 
months of treatment initiation, appear to increase over time, and may more than offset
the cost of IT.
